Biofrontera Belixos® now available
(Thomson Reuters ONE) - Corporate news announcement processed and transmitted by Hugin AS.The issuer is solely responsible for the content of this announcement. ------------------------------------------------------------------------------------ Leverkusen, Germany, - Biofrontera (DSE: B8F) today announces thattheir innovative medical cosmetic product Belixos® can, from now on,be purchased in Germany. In parallel to the market introduction, theproduct is, since yesterday evening, presented to an internationalexpert auditorium at the 18th Congress of the European Academy ofDermatology and Venerology (EADV) in Berlin.Belixos® was specifically designed for the intensive care of reddenedor itching skin, such as the skin problems occurring in psoriasis oratopic dermatitis. Belixos® combines herbal extracts, known from thetraditional medicine of the American Indians, with an innovative,proprietary biocolloid formulation.The active ingredients in Belixos® originate from Mahonia aquifolium,a plant that is similar to its local cognate berberis, as well asgreen tea and chamomile. Aided by the biocolloid technology the plantalkaloids very rapidly penetrate and diffuse around the epidermis,thus providing their soothing and regenerating effects particularlywithin this skin layer. The biocolloids are, in addition, responsiblefor the excellent cosmetic properties of the crème.The EADV congress, at which Belixos® is now, parallel to the marketlaunch, presented to an international expert group, is the largestEuropean dermatology congress at which the newest clinical resultsand scientific achievements are presented and discussed. At thecongress Biofrontera presents itself jointly with Grünenthal PharmaAG, which is manufacturing the product on Biofrontera's behalf.Belixos® is now immediately available through an internet shopreleased today (www.belixos.com). Next to the option of an onlineorder of the new product, the shop offers detailed information aboutBelixos® for both, medical experts and users."The market introduction of Belixos® is a pleasing event paving theway for the future development of the company. We are proud that ourfirst product can now be purchased, and we are awaiting the feed-backof the first users with curiosity. With Belixos® Biofrontera hasdeveloped a product that is specifically tailored at the needs of themany people suffering from divers skin problems," commented Prof.Hermann Lübbert, CEO of Biofrontera AG. "This market launchrepresents one of the 2009 milestones of the company which has nowsuccessfully been achieved. A new chapter in Biofrontera's companyhistory and the firm's outside perception has today been initiated."About Biofrontera AGBiofrontera AG is specialized in the development of pharmaceuticalproducts in the area of dermatology. The company is characterized bya broad, relatively close to the market product portfolio.Biofrontera is listed in the regulated market of the Düsseldorf stockexchange under the symbol B8F and the ISIN DE0006046113.This press release contains forward-looking statements based on thecurrently held beliefs and assumptions of the management ofBiofrontera AG, which are expressed in good faith and, in theiropinion, reasonable. Forward-looking statements involve known andunknown risks, uncertainties and other factors, which may cause theassumptions expressed or implied in this press release to be faulty.Given these risks, uncertainties and other factors, recipients ofthis document are cautioned not to place undue reliance on theforward-looking statements. Biofrontera AG disclaims any obligationto update these forward-looking statements to reflect future eventsor developments.For further information please contact:Anke zur MühlenCorporate Communication+ 49 (0) 214 87632 22+ 49 (0) 214 87632 90a.zurmuehlen(at)biofrontera.comBiofrontera AGHemmelrather Weg 201D- 51377 Leverkusen, GermanyThe press release can be downloaded from the following link:http://hugin.info/136349/R/1346404/323395.pdf --- End of Message ---Biofrontera AGHemmelrather Weg 201 Leverkusen GermanyWKN: 604611; ISIN: DE0006046113; Listed: Freiverkehr in Börse Berlin, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Stuttgart, Open Market (Freiverkehr) in Frankfurter Wertpapierbörse, Regulierter Markt in Börse Düsseldorf;
Datum: 08.10.2009 - 09:41 Uhr
Sprache: Deutsch
News-ID 6713
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 366 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Biofrontera Belixos® now available"
steht unter der journalistisch-redaktionellen Verantwortung von
Biofrontera AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
